1.
Evid. actual. práct. ambul
;
24(2): e002125, 2021. tab
Article
in Spanish
| LILACS
| ID: biblio-1255165
Subject(s)
Humans , Male , Female , Adult , Middle Aged , Young Adult , Tension-Type Headache/chemically induced , Tension-Type Headache/drug therapy , Analgesics/adverse effects , Outcome and Process Assessment, Health Care , Randomized Controlled Trials as Topic , Tension-Type Headache/prevention & control , Denmark , Migraine Disorders/drug therapy
2.
Article
in English
| IMSEAR
| ID: sea-87942
Subject(s)
Analgesics/therapeutic use , Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Antidepressive Agents, Tricyclic/therapeutic use , Chronic Disease , Humans , Neuromuscular Agents/therapeutic use , Selective Serotonin Reuptake Inhibitors/therapeutic use , Tension-Type Headache/prevention & control
3.
Article
in English
| IMSEAR
| ID: sea-91279
ABSTRACT
Nifedipine was evaluated in the prophylaxis of 28 patients each of migraine and tension headache using a double blind cross over design with random allocation to drug or placebo group. The duration of the trial was 3 months with a 2 week run-in period and 2 week wash-oat period separating two treatment periods of 4 weeks each. A satisfactory response was obtained in 71.4% of migraineurs (p < 0.001) and 28.6% of patients with tension headache (p = N.S). Minor side effects were observed in 5 patients. Nifedipine is a useful agent for the management of migraine as it reduces frequency and severity of pain but the drug cannot be recommended for tension headache.
Subject(s)
Adult , Calcium Channel Blockers/adverse effects , Cross-Over Studies , Double-Blind Method , Drug Administration Schedule , Female , Humans , Male , Migraine Disorders/prevention & control , Nifedipine/adverse effects , Tension-Type Headache/prevention & control , Time Factors
4.
Rev. Soc. Boliv. Med. Famil
;
1(1): 69-75, 1990.
Article
in Spanish
| LILACS
| ID: lil-196566